177 related articles for article (PubMed ID: 37604912)
1. Targeting SphK1/2 by SKI-178 inhibits prostate cancer cell growth.
Jin L; Zhu J; Yao L; Shen G; Xue BX; Tao W
Cell Death Dis; 2023 Aug; 14(8):537. PubMed ID: 37604912
[TBL] [Abstract][Full Text] [Related]
2. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
[TBL] [Abstract][Full Text] [Related]
3. The sphingosine kinase inhibitor SKI-V suppresses cervical cancer cell growth.
Zhang Y; Cheng L; Shi X; Song Y; Chen XY; Chen MB; Yao J; Zhang ZQ; Cai S
Int J Biol Sci; 2022; 18(7):2994-3005. PubMed ID: 35541904
[TBL] [Abstract][Full Text] [Related]
4. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V.
Sun X; Shan HJ; Yin G; Zhang XY; Huang YM; Li HJ
Cell Death Discov; 2022 Feb; 8(1):48. PubMed ID: 35115496
[TBL] [Abstract][Full Text] [Related]
5. GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms.
Jin L; Zhang W; Yao MY; Tian Y; Xue BX; Tao W
Cell Death Discov; 2022 Mar; 8(1):120. PubMed ID: 35296639
[TBL] [Abstract][Full Text] [Related]
6. A first-in-class TIMM44 blocker inhibits bladder cancer cell growth.
Zhang L; Shi X; Zhang L; Mi Y; Zuo L; Gao S
Cell Death Dis; 2024 Mar; 15(3):204. PubMed ID: 38467612
[TBL] [Abstract][Full Text] [Related]
7. GDC-0349 inhibits non-small cell lung cancer cell growth.
Yang H; Zhao J; Zhao M; Zhao L; Zhou LN; Duan Y; Li G
Cell Death Dis; 2020 Nov; 11(11):951. PubMed ID: 33154352
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells.
Yang YL; Ji C; Cheng L; He L; Lu CC; Wang R; Bi ZG
Cancer Sci; 2012 Aug; 103(8):1538-45. PubMed ID: 22594559
[TBL] [Abstract][Full Text] [Related]
9. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
[TBL] [Abstract][Full Text] [Related]
11. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
[TBL] [Abstract][Full Text] [Related]
12. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.
Yang L; Weng W; Sun ZX; Fu XJ; Ma J; Zhuang WF
Biochem Biophys Res Commun; 2015 May; 460(4):903-8. PubMed ID: 25824043
[TBL] [Abstract][Full Text] [Related]
13. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism.
Maceyka M; Sankala H; Hait NC; Le Stunff H; Liu H; Toman R; Collier C; Zhang M; Satin LS; Merrill AH; Milstien S; Spiegel S
J Biol Chem; 2005 Nov; 280(44):37118-29. PubMed ID: 16118219
[TBL] [Abstract][Full Text] [Related]
14. Targeting sphingosine kinase-1 to inhibit melanoma.
Madhunapantula SV; Hengst J; Gowda R; Fox TE; Yun JK; Robertson GP
Pigment Cell Melanoma Res; 2012 Mar; 25(2):259-74. PubMed ID: 22236408
[TBL] [Abstract][Full Text] [Related]
15. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.
Pchejetski D; Golzio M; Bonhoure E; Calvet C; Doumerc N; Garcia V; Mazerolles C; Rischmann P; Teissié J; Malavaud B; Cuvillier O
Cancer Res; 2005 Dec; 65(24):11667-75. PubMed ID: 16357178
[TBL] [Abstract][Full Text] [Related]
17. The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.
Zhang D; Xia H; Zhang W; Fang B
Tumour Biol; 2016 Jan; 37(1):1327-36. PubMed ID: 26293898
[TBL] [Abstract][Full Text] [Related]
18. Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR.
Deeb D; Gao X; Jiang H; Dulchavsky SA; Gautam SC
Prostate; 2009 Jun; 69(8):851-60. PubMed ID: 19189297
[TBL] [Abstract][Full Text] [Related]
19. Hispidulin mediates apoptosis in human renal cell carcinoma by inducing ceramide accumulation.
Gao H; Gao MQ; Peng JJ; Han M; Liu KL; Han YT
Acta Pharmacol Sin; 2017 Dec; 38(12):1618-1631. PubMed ID: 29119970
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic value of SC66 in human renal cell carcinoma cells.
Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
